How can we use AI to program antibodies?

About this episode

The episode discusses an AI-driven approach to drug development with a focus on programmable antibodies and their potential in treating cancer and autoimmune diseases.

This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. We are joined by Yanay Ofran, chief executive and founder of Israel-based Biolojic Design, a company that is working on programmable antibodies. Biolojic's platform has already yielded a first-of-its-kind computationally designed antibody, now in Phase II trials, as well as a pipeline aimed at autoimmune and inflammatory conditions. The firm ...

People in this episode

Host: Simon Wentworth

Guest: Yanay Ofran

Topics covered

• AI in drug development
• programmable antibodies
• cancer treatment
• autoimmune diseases
• computational design

Keywords

• AI
• drug development
• antibodies
• cancer
• autoimmune diseases
• Biolojic Design
• computational design

Mentioned in this episode

Organizations: Biolojic Design, Israel

More episodes of The Pharma Letter Podcast

• BenevolentAI CEO on the future of AI-led medicine · May 6, 2026 · 30 min
• ConcertAI CEO Eron Kelly on Big Tech's role in biotech · March 13, 2026 · 18 min
• How blood cancer treatment is evolving in the Middle East · December 8, 2025 · 22 min
• Nouscom bets on dual vaccine strategy to outsmart cancer · July 25, 2025 · 20 min
• Is this a revolution in Alzheimer's? · June 12, 2025 · 21 min
• Why Boehringer and GSK are betting on Ochre · May 23, 2025 · 19 min